Excellent Science for New Therapies

Chronic inflammmation, triggered by dysfunctions on the boundary surfaces of the body’s organs and their interaction with the environment, represents a central challenge for modern medicine. It is considered to be the cause of many chronic diseases, which have been steadily increasing in recent decades – especially in western industrialized countries. The goal of the Cluster of Excellence in Inflammation Research is to decode the molecular basis of chronic inflammatory diseases, as well as the complete identification of metabolic and signaling pathways as an approach to therapies and prevention. The unforeseen complexity and the breadth of possible triggers of inflammatory diseases require new scientific structures and practices. In the Excellence Cluster, key elements of the origins of inflammation will be examined in detail on genetic, genomic and functional levels. The cluster is a joint venture of Kiel University and the University of Lübeck, together with the Schleswig-Holstein University Medical Center, the Leibniz Research Center Borstel, the Max Planck Institute for Evolutionary Biology, Plön, and the Muthesius Academy of Fine Arts and Design in Kiel. More: www.inflammation-qt-interfaces.de
Picture: David Ellinghaus

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …